收藏切换
Discussion on improving the medical insurance access of high-value orphan drugs in China under the basic medical insurance system
收藏切换
Lin ZHU1, Jiahao HU1, Yuhan LIU1, Fen LI1, 2, Chunlin JIN1, *
World Clinical Drug | 2023, 44(9) : 994 - 1000
Less
收藏切换
World Clinical Drug | 2023, 44(9): 994-1000
• Pharmacy administration •
Discussion on improving the medical insurance access of high-value orphan drugs in China under the basic medical insurance system
Full
Lin ZHU1, Jiahao HU1, Yuhan LIU1, Fen LI1, 2, Chunlin JIN1, *
Affiliations
  • 1.Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai 200040, China
  • 2.Financial Management Center of Shanghai Municipal Health Commission, Shanghai 200040, China
Published: 2023-09-10 doi: 10.13683/j.wph.2023.09.017
Outline
收藏切换

High-value orphan drugs for rare diseases can fill the clinical therapeutic gaps and significantly improve symptoms and patients' quality of life compared with standard treatment regimens. However, due to uncertainties in the number of patients, real-world efficacy and safety performance of drug, and fund budget impact and other factors, the decision-making risk of the medical insurance department is extremely uncertain. The high price also leads to the increasing difficulty of medical insurance access. Due to the particularity of rare diseases, there are certain limitations in drug list adjustments using the same selection and evaluation principle of conventional drugs and following the track of "strict access, loose extension" for high-value orphan drugs. According to the international experience, the medical insurance access of rare disease drugs needs a differentiated evaluation system. This article explored the dilemma of medical insurance access for high-value orphan drugs and analyzes the causes. Drawing on international experiences and combining with domestic medical insurance access practice, we put forward some ideas to improve the medical insurance access for high-value orphan drugs in China, in order to provide references for relevant department to make adjustments on the medical security for rare diseases and innovate the selection and evaluation mechanism, and further improve the accessibility of high-value orphan drugs for patients with rare diseases.

medical insurance system  /  rare disease  /  medical insurance access  /  drug selection  /  value assessment
朱琳, 胡嘉浩, 刘宇晗, 李芬, 金春林. 基本医疗保障制度下完善我国罕见病高价值治疗药物医保准入的思路探讨. 世界临床药物, 2023 , 44 (9) : 994 -1000 . DOI: 10.13683/j.wph.2023.09.017
Lin ZHU, Jiahao HU, Yuhan LIU, Fen LI, Chunlin JIN. Discussion on improving the medical insurance access of high-value orphan drugs in China under the basic medical insurance system[J]. World Clinical Drug, 2023 , 44 (9) : 994 -1000 . DOI: 10.13683/j.wph.2023.09.017
Year 2023 volume 44 Issue 9
12
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.09.017
  • Receive Date:2023-05-08
  • Online Date:2026-11-18
  • Published:2023-09-10
Article Data
Affiliations
History
  • Received:2023-05-08
Funding
Affiliations
    1.Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai 200040, China
    2.Financial Management Center of Shanghai Municipal Health Commission, Shanghai 200040, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.09.017
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT